Combination of photodynamic therapy with anti-cancer agents.

@article{Zuluaga2008CombinationOP,
  title={Combination of photodynamic therapy with anti-cancer agents.},
  author={Mar{\'i}a-Fernanda Zuluaga and Norbert Lange},
  journal={Current medicinal chemistry},
  year={2008},
  volume={15 17},
  pages={
          1655-73
        }
}
Degenerative diseases such as cancer usually involve more than one pathological process. Therefore, attempts to combat such diseases with monotherapeutic approaches may not always do so efficiently. For this reason, the use of combination therapy with modalities that target different disease pathways represents an alternative strategy. Photodynamic therapy (PDT) has already been established as an alternative therapy for the treatment of various types of malignant disorders, including… 

Tables from this paper

Combination approaches to potentiate immune response after photodynamic therapy for cancer.

  • Tyler G. St. DenisK. Aziz M. Hamblin
  • Biology
    Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology
  • 2011
By understanding the methods employed by tumors to evade immune response and neutralizing them, more precise ways of potentiating PDT-induced immunity can be devised.

Strategies to potentiate immune response after photodynamic therapy

  • M. Hamblin
  • Biology
    Photonics West - Biomedical Optics
  • 2015
By understanding the methods employed by tumors to evade immune response and neutralizing them, more precise ways of potentiating PDT-induced immunity can be devised.

Enhancing Photodynamyc Therapy Efficacy by Combination Therapy: Dated, Current and Oncoming Strategies

This short review is concerned with therapeutic combinations in which PDT (Photodynamyc Therapy) is the core therapeutic partner and the principal methods used to assess the efficacy attained by combinations in respect to monotherapy.

The role of photodynamic therapy in overcoming cancer drug resistance.

  • B. SpringI. RizviNan XuT. Hasan
  • Biology
    Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology
  • 2015
Key preclinical findings utilizing PDT to overcome classical drug resistance or escape pathways and thus enhance the efficacy of many pharmaceuticals are highlighted, possibly explaining the clinical observations of the PDT response to otherwise treatment-resistant diseases.

Approaches to improve photodynamic therapy of cancer.

Novel strategies for further potentiation of the anticancer effectiveness of PDT have been developed, including combined treatments with surgery, chemo- and radiotherapy, strategies targeting cytoprotective mechanisms induced in PDT-treated cells, as well as attempts aimed at enhancement of PDT-mediated antitumor immune response.

Polymeric Nanoparticles for Cancer Photodynamic Therapy.

Delivery of PSs through NPs offers a great opportunity to overcome PDT drawbacks based on the concept that a nanocarrier can drive therapeutic concentrations of PS to the tumor cells without generating any harmful effect in non-target tissues, which can severely affect photophysical, chemical, and biological properties.

Photodynamic Therapy for Cancer: Principles, Clinical Applications, and Nanotechnological Approaches

Clinical studies reveal that PDT can be curative, particularly in early stage tumors, can prolong survival in patients with inoperable cancers, and can significantly improve quality of life.

Photodynamic Synergistic Effect of Pheophorbide a and Doxorubicin in Combined Treatment against Tumoral Cells

Results indicate that an appropriate combination of DOXO with PhA and red light may produce improved cytotoxicity with a smaller dose of the chemotherapeutic drug, as a result of the different subcellular localization, targets and mode of action of the two agents.
...

References

Combination of Photodynamic Therapy with Anti-Cancer Agents Current Medicinal Chemistry

  • J. Environ. Pathol. Toxicol. Oncol.,
  • 2006